Visceral hypersensitivity in symptomatic diverticular disease and the role of neuropeptides and low grade inflammation

Neurogastroenterology and Motility

Volumn 24, Issue 4, 2012, Pages

  Humes, D J ^a   Simpson, J ^a   Smith, J ^a   Sutton, P ^a   Zaitoun, A ^a   Bush, D ^a   Bennett, A ^b   Scholefield, J H ^a   Spiller, R C ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Diverticular disease; Inflammation; Tachykinin; Visceral hypersensitivity

Indexed keywords

CD3 ANTIGEN; GALANIN RECEPTOR 1; INTERLEUKIN 6; MESSENGER RNA; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR; NEUROPEPTIDE; SEROTONIN; SUBSTANCE P; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BAROSTAT; CLINICAL ARTICLE; DISEASE ASSOCIATION; DIVERTICULOSIS; FEMALE; GASTROINTESTINAL BIOPSY; HUMAN; HUMAN TISSUE; HYPERSENSITIVITY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SIGMOIDOSCOPY; VISCERAL HYPERSENSITIVITY;

ABDOMINAL PAIN; AGED; DIVERTICULITIS, COLONIC; DIVERTICULOSIS, COLONIC; FEMALE; HUMANS; HYPERESTHESIA; INFLAMMATION; MALE; MIDDLE AGED; NEUROPEPTIDES; PAIN THRESHOLD; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, NEUROPEPTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VISCERA;

EID: 84862806750     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2011.01863.x     Document Type: Article

References (44)

1. Simpson J, Neal KR, Scholefield JH, Spiller RC. Patterns of pain in diverticular disease and the influence of acute diverticulitis. Eur J Gastroenterol Hepatol 2003; 15: 1-6.
2. Humes DJ, Simpson J, Neal KR, Scholefield JH, Spiller RC. Psychological and colonic factors in painful diverticulosis. Br J Surg 2008; 95: 195-8.
3. Simpson J, Scholefield JH, Spiller RC. Origin of symptoms in diverticular disease. Br J Surg 2003; 90: 899-908.
4. Clemens CHM, Samsom M, Roelofs J, van Berge Henegouwen GP, Smout AJPM. Colorectal visceral perception in diverticular disease. Gut 2004; 53: 717-22.
5. Simpson J, Spiller R. Colonic diverticular disease. Clin Evid 2004; 12: 599-609.
6. Horgan AF, McConnell EJ, Wolff BG, The S, Paterson C. Atypical diverticular disease: surgical results. Dis Colon Rectum 2001; 44: 1315-8.
7. Moreaux J, Vons C. Elective resection for diverticular disease of the sigmoid colon. Br J Surg 1990; 77: 1036-8.
8. Tursi A, Brandimarte G, Giorgetti G, Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol 2006; 40: 312-6.
9. Simpson J, Sundler F, Humes DJ, Jenkins D, Scholefield JH, Spiller RC. Post inflammatory damage to the enteric nervous system in diverticular disease and its relationship to symptoms. Neurogastroenterol Motil 2009; 21: 847-58.
10. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
11. Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002; 64: 258-66.
12. Spiller RC, Humes DJ, Campbell E et al. The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. Aliment Pharmacol Ther 2010; 32: 811-20.
13. Jenkins D, Balsitis M, Gallivan S et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. J Clin Pathol 1997; 50: 93-105.
14. Whitehead WE, Delvaux M. Standardization of barostat procedures for testing smooth muscle tone and sensory thresholds in the gastrointestinal tract. The Working Team of Glaxo-Wellcome Research, UK. Dig Dis Sci 1997; 42: 223-41.
15. Cremonini F, Houghton L, Camilleri M et al. Barostat testing of rectal sensation and compliance in humans: comparison of results across two centres and overall reproducibility. Neurogastroenterol Motil 2005; 17: 810-20.
16. Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. gut 2000; 47: 804-11.
17. Rasband WS. Image J, Bethesda, Maryland, USA: U. S. National Institutes of Health, 1997-2009.
18. Rossel P, Drewes AM, Petersen P, Nielsen J, Arendt-Nielsen L. Pain produced by electric stimulation of the rectum in patients with irritable bowel syndrome: further evidence of visceral hyperalgesia. Scand J Gastroenterol 1999; 34: 1001-6.
19. Chadwick VS, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-83.
20. Jonsson M, Norrgard O, Forsgren S. Substance P and the neurokinin-1 receptor in relation to eosinophilia in ulcerative colitis. Peptides 2005; 26: 799-814.
21. Baker SJ, Morris JL, Gibbins IL. Cloning of a C-terminally truncated NK-1 receptor from guinea-pig nervous system. Brain Res Mol Brain Res 2003; 111: 136-47.
22. Beaujouan JC, Saffroy M, Torrens Y, Glowinski J. Different subtypes of tachykinin NK(1) receptor binding sites are present in the rat brain. J Neurochem 2000; 75: 1015-26.
23. Gillespie E, Leeman SE, Watts LA et al. Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer. Proc Natl Acad Sci U S A 2011; 108: 17420-5.
24. Bandari PS, Qian J, Yehia G et al. Differences in the expression of neurokinin receptor in neural and bone marrow mesenchymal cells: implications for neuronal expansion from bone marrow cells. Neuropeptides 2002; 36: 13-21.
25. Yip L, Kwok YN, Buchan AM. Cellular localization and distribution of neurokinin-1 receptors in the rat stomach. Auton Neurosci 2003; 104: 95-108.
26. Forsgren S, Danielson P, Alfredson H. Vascular NK-1 receptor occurrence in normal and chronic painful Achilles and patellar tendons: studies on chemically unfixed as well as fixed specimens. Regul Pept 2005; 126: 173-81.
27. Southwell BR, Furness JB. Immunohistochemical demonstration of the NK(1) tachykinin receptor on muscle and epithelia in guinea pig intestine. Gastroenterology 2001; 120: 1140-51.
28. Matuszek MA, Burcher E. Smooth muscle, neurons and interstitial cells of guinea pig ileum: are there tachykinin neurokinin 1 receptor subtypes? Pharmacology 2002; 66: 61-7.
29. Burcher E, Shang F, Warner FJ et al. Tachykinin NK2 receptor and functional mechanisms in human colon: changes with indomethacin and in diverticular disease and ulcerative colitis. J Pharmacol Exp Ther 2008; 324: 170-8.
30. Liu L, Markus I, Saghire HE, Perera DS, King DW, Burcher E. Distinct differences in tachykinin gene expression in ulcerative colitis, Crohn's disease and diverticular disease: a role for hemokinin-1? Neurogastroenterol Motil 2011; 23: 475-83. e179-80.
31. Liu L, Shang F, Morgan MJ, King DW, Lubowski DZ, Burcher E. Cyclooxygenase-dependent alterations in substance P-mediated contractility and tachykinin NK1 receptor expression in the colonic circular muscle of patients with slow transit constipation. J Pharmacol Exp Ther 2009; 329: 282-9.
32. Goode T, O'Connell J, Anton P et al. Neurokinin-1 receptor expression in inflammatory bowel disease: molecular quantitation and localisation. Gut 2000; 47: 387-96.
33. Hawes JJ, Brunzell DH, Wynick D, Zachariou V, Picciotto MR. GalR1, but not GalR2 or GalR3, levels are regulated by galanin signaling in the locus coeruleus through a cyclic AMP-dependent mechanism. J Neurochem 2005; 93: 1168-76.
34. Lu X, Bartfai T. Analyzing the validity of GalR1 and GalR2 antibodies using knockout mice. Naunyn Schmiedebergs Arch Pharmacol 2009; 379: 417-20.
35. Kang JY, Firwana B, Green AE et al. Uncomplicated diverticular disease is not a common cause of colonic symptoms. Aliment Pharmacol Ther 2011; 33: 487-94.
36. Bassotti G, Battaglia E, De Roberto G, Morelli A, Tonini M, Villanacci V. Alterations in colonic motility and relationship to pain in colonic diverticulosis. Clin Gastroenterol Hepatol 2005; 3: 248-53.
37. Dorn SD, Palsson OS, Thiwan SIM et al. Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut 2007; 56: 1202-9.
38. Berman SM, Naliboff BD, Suyenobu B et al. Reduced brainstem inhibition during anticipated pelvic visceral pain correlates with enhanced brain response to the visceral stimulus in women with irritable bowel syndrome. J Neurosci 2008; 28: 349-59.
39. Wilder-Smith CH, Schindler D, Lovblad K, Redmond SM, Nirkko A. Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls. Gut 2004; 53: 1595-601.
40. Coffin B, Bouhassira D, Sabaté JM, Barbe L, Jian R. Alteration of the spinal modulation of nociceptive processing in patients with irritable bowel syndrome. Gut 2004; 53: 1465-70.
41. Di Mario F, Aragona G, Leandro G et al. Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Dig Dis Sci 2005; 50: 581-6.
42. Latella G, Pimpo M, Sottili S et al. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003; 18: 55-62.
43. Papi C, Ciaco A, Koch M, Capurso L. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 1995; 9: 33-9.
44. Holzer P. Gastrointestinal afferents as targets of novel drugs for the treatment of functional bowel disorders and visceral pain. Eur J Pharmacol 2001; 429: 177-93.